Intratumoral administration of viral vectors expressing IFNg represents a promising strategy for immunomodulation of the TME, especially for locally advanced tumors (breast cancer, prostate cancer), which allows i.t. administration to avoid the systemic toxicity of IFNg [84]. Here, IFNG is linked to breast carcinoma.